Novartis AG (NVS)
162.40
+1.14
(+0.71%)
USD |
NYSE |
Sep 02, 16:00
162.40
0.00 (0.00%)
After-Hours: 17:35
Novartis Research and Development Expense (Annual) : 10.74B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 10.74B |
| December 31, 2024 | 9.506B |
| December 31, 2023 | 8.223B |
| December 31, 2022 | 8.077B |
| December 31, 2021 | 9.54B |
| December 31, 2020 | 9.034B |
| December 31, 2019 | 9.402B |
| December 31, 2018 | 8.508B |
| December 31, 2017 | 8.972B |
| December 31, 2016 | 9.039B |
| December 31, 2015 | 8.935B |
| December 31, 2014 | 9.086B |
| December 31, 2013 | 9.104B |
| December 31, 2012 | 9.307B |
| December 31, 2011 | 9.391B |
| December 31, 2010 | 8.929B |
| December 31, 2009 | 7.259B |
| Date | Value |
|---|---|
| December 31, 2008 | 7.217B |
| December 31, 2007 | 6.43B |
| December 31, 2006 | 5.351B |
| December 31, 2005 | 4.817B |
| December 31, 2004 | 4.166B |
| December 31, 2003 | 3.729B |
| December 31, 2002 | 2.789B |
| December 31, 2001 | 2.481B |
| December 31, 2000 | 2.756B |
| December 31, 1999 | 2.823B |
| December 31, 1998 | 2.571B |
| December 31, 1997 | 2.546B |
| December 31, 1996 | 2.959B |
| December 31, 1995 | 2.986B |
| December 31, 1994 | 2.771B |
| December 31, 1993 | 2.670B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Roche Holding AG | 14.69B |
| AstraZeneca PLC | 13.84B |
| Johnson & Johnson | 14.83B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |